China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)

China Pharma Holdings' (CPHI) quarterly Convertible Debt came in at $4.8 million in Q2 2022, down 4.04% on a QoQ basis from $5.0 million in Q1 2022.

China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022) Analysis & Trends

China Pharma Holdings (CPHI) has 2 years of Convertible Debt data on file, last reported at $4.8 million in Q2 2022.

Quarterly Convertible Debt changed N/A year-over-year to $4.8 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $4.8 million (changed N/A YoY) and the FY2021 annual result came in at $5.2 million, changed N/A from the prior year.
Convertible Debt eased to $4.8 million in Q2 2022, from $5.0 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $5.2 million in Q4 2021 to a low of $4.8 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-
10	China Pharma Holdings	42.35 Mn	42.04 Mn	83,566.00

Download Data